News articles about STAAR Surgical (NASDAQ:STAA) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.5233010691013 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
STAAR Surgical (NASDAQ:STAA) opened at $16.85 on Friday. STAAR Surgical has a one year low of $8.95 and a one year high of $17.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.24 and a quick ratio of 1.72.
STAA has been the subject of several recent research reports. Zacks Investment Research raised STAAR Surgical from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Saturday, September 23rd. Canaccord Genuity boosted their price target on STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 17th. BidaskClub raised STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Benchmark reissued a “buy” rating and issued a $21.00 price target on shares of STAAR Surgical in a research report on Monday, November 20th. Finally, TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research note on Tuesday, August 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $17.67.
In other STAAR Surgical news, VP Keith Holliday sold 6,000 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total transaction of $99,900.00. Following the sale, the vice president now owns 45,969 shares in the company, valued at approximately $765,383.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.60% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect STAAR Surgical (STAA) Stock Price” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://ledgergazette.com/2017/12/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-staar-surgical-staa-stock-price.html.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.